SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 5.1% Stake in Dyne Therapeutics
Beneficial Ownership Disclosure
RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a 5.1% beneficial ownership stake in Dyne Therapeutics, Inc., holding 5,218,641 shares as of December 31, 2024.
Summary
- RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Dyne Therapeutics, Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 5,218,641 shares of Dyne Therapeutics, Inc. Common Stock.
- This ownership represents 5.1% of the total outstanding shares of Dyne Therapeutics, Inc. Common Stock.
- The percentage is calculated based on 101,765,958 shares outstanding as of November 8, 2024, as reported in the Company's Quarterly Report on Form 10-Q.
- Both RTW Investments, LP and Dr. Wong have shared voting power and shared dispositive power over all 5,218,641 shares.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain performance or operational information to assess sentiment beyond the neutral act of reporting a stake. The act of an institutional investor taking a significant stake can be viewed positively by some, but the document itself is neutral.
Positives
- The disclosure of a significant stake (5.1%) by an institutional investor like RTW Investments, LP, and its Managing Partner, Dr. Roderick Wong, can be viewed as a positive signal of confidence in Dyne Therapeutics, Inc. by some investors.
Future Outlook
NA
Industry Context
This filing is a standard regulatory disclosure for significant ownership stakes in publicly traded companies, common across all industries, including biotechnology. It indicates an investment firm's position in a company rather than providing operational or strategic insights specific to the biotechnology sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence investor perception and potentially stock liquidity. It signals that a notable investment firm has a stake in the company.
Key Dates
| Date | Description |
|---|---|
| 11/08/2024 | Date as of which 101,765,958 shares outstanding were reported in Dyne Therapeutics' Form 10-Q. |
| 12/31/2024 | Date of event which required the filing of this statement (beneficial ownership calculation date). |
| 02/14/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Dyne Therapeutics, RTW Investments, Roderick Wong, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.